May 2015 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2014/15 Invitation to Tender, dated 6 November 2014.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018
CORRECTION to April 2015 tender notification: in bold and strikethrough
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Zopiclone 1 | Tab 7.5 mg; 500 tablet |
$11.90 | $8.99 | Zopiclone Actavis (Actavis) |
1 October 2015 | 1 December 2015 | 1 March 2016 | Apo-Zopiclone (Apotex) |
1 Brand switch fee of $4.33 is payable for this product from 1 March 2016 until 1 June 2016
CORRECTION to April 2015 tender notification: in bold and strikethrough
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack Price | Hospital SupplyBrand (Supplier) | DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Zopiclone | Tab 7.5 mg; 500 tablet, |
Zopiclone Actavis (Actavis) |
1% | 1 October 2015 | 1 December 2015 |
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) |
Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Pancreatic enzyme | Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease; 100 capsule, bottle pack |
$94.38 | $94.38 | Creon 25000 (Abbott) |
1 August 2015 | 1 November 2015 |
| Pancreatic enzyme | Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease; 100 capsule, bottle pack |
$34.93 | $34.93 | Creon 10000 (Abbott) |
1 August 2015 | 1 November 2015 |
| Paracetamol | Suppos 500 mg; 50 suppositories |
$20.70 | $12.60 | Paracare (API) |
1 September 2015 | 1 December 2015 |
| Sodium cromoglycate | Eye drops 2%; 5 ml OP |
$1.18 | $0.85 | Rexacrom (Rex Medical) |
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current subsidy (and price) |
New subsidy (and price) |
Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date (and delisting of other listed brands) |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Acetylcysteine1 |
Inj 200 mg per ml, 10 ml ampoule; 10 ampoules |
$178.00 |
$78.34 |
DBL Acetylcysteine (Hospira) |
1 July 2015 |
1 September 2015 |
1 December 2015 |
Martindale Acetylcysteine (Max Health) Acetadote (AFT) |
|
Bosentan |
Tab 62.5 mg; 56 tablet, blister pack |
$1,500.00 per 60 tablets, and $4,585.00 per 60 tablets |
$375.00 per 56 tablets |
Mylan-Bosentan (Mylan) |
1 August 2015 |
1 December 2015 |
1 March 2016 |
Pms-Bosentan (AFT) Tracleer (Actelion) |
|
Bosentan |
Tab 125 mg; 56 tablet, blister pack |
$1,500.00 per 60 tablets, and $4,585.00 per 60 tablets |
$375.00 per 56 tablets |
Mylan-Bosentan (Mylan) |
1 August 2015 |
1 December 2015 |
1 March 2016 |
Pms-Bosentan (AFT) Tracleer (Actelion) |
|
Chlorhexidine gluconate |
Soln 4% wash; 500 ml |
$5.90 |
$3.98 |
healthE (Jaychem) |
1 August 2015 |
1 October 2015 |
1 January 2016 |
Orion (Orion) |
|
Citalopram hydrobromide 2 |
Tab 20 mg; 84 tablet, blister pack |
$2.34 |
$1.79 |
PSM Citalopram (API) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Arrow-Citalopram (Actavis) |
|
Cyclizine hydrochloride |
Tab 50 mg; 20 tablet, blister pack |
$0.59 per 10 tablets |
$0.59 per 20 tablets |
Nauzene (Actavis) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
Nausicalm (AFT) |
|
Desferrioxamine mesilate |
Inj 500 mg vial; 10 vials |
$109.89 |
$51.52 |
Desferal (Novartis) |
1 December 2015 |
1 February 2016 |
1 May 2016 |
Hospira (Hospira) |
|
Dexamethasone3 |
Tab 0.5 mg; 30 tablet, bottle pack |
$5.87 per 100 tablets of tab 1 mg |
$0.88 per 30 tablets of tab 0.5 mg |
Dexmethsone (Aspen) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
Douglas (Douglas) |
|
Dexamethasone |
Tab 4 mg; 30 tablet, bottle pack |
$8.16 per 100 tablets |
$1.84 per 30 tablets |
Dexmethsone (Aspen) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
Douglas (Douglas) |
|
Lansoprazole |
Cap 15 mg; 100 capsule, bottle pack |
$2.00 per 28 |
$5.08 per 100 |
Lanzol Relief (Mylan) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
Solox (Douglas) |
|
Lansoprazole |
Cap 30 mg; 100 capsule, bottle pack |
$2.32 per 28 |
$5.93 per 100 |
Lanzol Relief (Mylan) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
Solox (Douglas) |
|
Metformin hydrochloride |
Tab immediate-release 850 mg; 500 tablet, bottle pack |
$10.10 |
$7.82 |
Metformin Mylan (Mylan) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Apotex (Apotex) |
|
Oil in water emulsion |
Crm; 500 g |
$2.63 |
$2.25 |
O/W Fatty Emulsion Cream (Boucher) |
1 November 2015 |
1 January 2016 |
1 April 2016 |
healthE Fatty Cream (Jaychem) |
|
Paracetamol |
Suppos 125 mg; 10 suppositories |
$7.49 per 20 |
$3.69 per 10 |
Gacet (AFT) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Panadol (GSK) |
|
Paracetamol |
Suppos 250 mg; 10 suppositories |
$14.40 per 20 |
$3.79 per 10 |
Gacet (AFT) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Panadol (GSK) |
|
Pioglitazone |
Tab 15 mg; 90 tablet, bottle pack |
$1.50 per 28 tablets |
$3.47 per 90 tablets |
Vexazone (Mylan) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Pizaccord (Douglas) |
|
Pioglitazone |
Tab 30 mg; 90 tablet, bottle pack |
$2.50 per 28 tablets |
$5.06 per 90 tablets |
Vexazone (Mylan) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Pizaccord (Douglas) |
|
Pioglitazone |
Tab 45 mg; 90 tablet, bottle pack |
$3.50 per 28 tablets |
$7.10 per 90 tablets |
Vexazone (Mylan) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Pizaccord (Douglas) |
-
Acetylcysteine inj 200 mg per ml, 30 ml will have a subsidy reduction from 1 September 2015 and will be delisted from Section B from 1 December 2015.
-
Brand switch fee of $4.33 is payable for this product from 1 March 2016 until 1 June 2016.
-
Dexamethasone tab 1 mg to be delisted 1 April 2016.
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Hospital Supply Brand(Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Carmustine |
Inj 100 mg vial; 1 vial |
$532.00 |
$532.00 |
BiCNU (Actavis) |
1% |
1 July 2015 |
1 September 2015 |
|
Flumazenil |
Inj 0.1 mg per ml, 5 ml ampoule; 5 ampoules |
$170.10 |
$85.05 |
Anexate (Roche) |
1% |
1 July 2015 |
1 September 2015 |
|
Fluorouracil 1 |
Inj 50 mg per ml, 20 ml vial; 1 vial |
$7.50 |
$10.00 |
Fluorouracil Ebewe (Sandoz) |
1% |
1 August 2015 |
1 October 2015 |
|
Fluorouracil 1 |
Inj 50 mg per ml, 50 ml vial; 1 vial |
$18.00 |
$17.00 |
Fluorouracil Ebewe (Sandoz) |
1% |
1 August 2015 |
1 October 2015 |
|
Fluorouracil 1 |
Inj 50 mg per ml, 100 ml vial; 1 vial |
$34.50 |
$30.00 |
Fluorouracil Ebewe (Sandoz) |
1% |
1 August 2015 |
1 October 2015 |
|
Irinotecan hydrochloride 2 |
Inj 20 mg per ml, 2 ml vial; 1 vial |
$9.34 |
$11.50 |
Irinotecan Actavis 40 (Actavis) |
1% |
1 July 2015 |
1 September 2015 |
|
Irinotecan hydrochloride 2 |
Inj 20 mg per ml, 5 ml vial; 1 vial |
$23.34 |
$17.80 |
Irinotecan Actavis 100 (Actavis) |
1% |
1 July 2015 |
1 September 2015 |
|
Mitozantrone 3 |
Inj 2 mg per ml, 10 ml vial; 1 vial |
$100.00 |
$97.50 |
Mitozantrone Ebewe (Sandoz) |
1% |
1 July 2015 |
1 September 2015 |
|
Paracetamol |
Suppos 500 mg; 50 suppositories |
$20.70 |
$12.60 |
Paracare (API) |
1% |
1 September 2015 |
1 November 2015 |
|
Tranexamic acid |
Inj 100 mg per ml, 5 ml ampoule; 10 ampoules |
$124.73 |
$55.00 |
Cyklokapron (Pfizer) |
1% |
1 July 2015 |
1 September 2015 |
-
The price and subsidy of fluorouracil (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 August 2015. The subsidy for fluorouracil inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $0.77 per 100 mg to $0.66 per 100 mg from 1 August 2015. Fluorouracil Ebewe inj 50 mg per ml, 10 ml vial to be delisted from Section H from 1 October 2015.
-
The price and subsidy of irinotecan hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2015. The subsidy for irinotecan hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $0.24 per 1 mg to $0.19 per 1 mg from 1 July 2015.
-
The price and subsidy of mitozantrone (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 July 2015. The subsidy for mitozantrone inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $5.65 per 1 mg to $5.51 per 1 mg from 1 July 2015. Mitozantrone Ebewe inj 2 mg per ml, 5 ml vial and Onkotrone inj 2 mg per ml, 12.5 ml vial to be delisted from 1 January 2016.
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Acetylcysteine1 |
Inj 200 mg per ml, 10 ml ampoule; 10 ampoules |
$178.00 |
$78.34 |
DBL Acetylcysteine (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
Martindale Acetylcysteine (Max Health) Acetadote (AFT) |
|
Aciclovir |
Inj 250 mg vial; 5 vials |
$14.09 |
$10.10 |
Aciclovir-Claris (AFT) |
1% |
1 November 2015 |
1 January 2016 |
Zovirax IV (GSK) |
|
Bosentan |
Tab 62.5 mg; 56 tablet, blister pack |
$1,500.00 per 60 tablets, and $4,585.00 per 60 tablets |
$375.00 per 56 tablets |
Mylan-Bosentan (Mylan) |
1% |
1 August 2015 |
1 December 2015 |
Pms-Bosentan (AFT) Tracleer (Actelion)
|
|
Bosentan |
Tab 125 mg; 56 tablet, blister pack |
$1,500.00 per 60 tablets, and $4,585.00 per 60 tablets |
$375.00 per 56 tablets |
Mylan-Bosentan (Mylan) |
1% |
1 August 2015 |
1 December 2015 |
Pms-Bosentan (AFT) Tracleer (Actelion)
|
|
Carboplatin2 |
Inj 10 mg per ml, 5 ml vial; 1 vial |
$20.00 |
$15.07 |
DBL Carboplatin (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
Carboplatin Ebewe (Sandoz) |
|
Carboplatin2 |
Inj 10 mg per ml, 15 ml vial; 1 vial |
$19.50 |
$14.05 |
DBL Carboplatin (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
Carbaccord (Actavis) |
|
Carboplatin2 |
Inj 10 mg per ml, 45 ml vial; 1 vial |
$48.50 |
$32.59 |
DBL Carboplatin (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
Carbaccord (Actavis) |
|
Cefepime hydrochloride |
Inj 1 g vial; 1 vial |
$8.80 |
$3.95 |
Cefepime-AFT (AFT) |
1% |
1 August 2015 |
1 October 2015 |
DBL Cefepime (Hospira) |
|
Cefepime hydrochloride |
Inj 2 g vial; 1 vial |
$17.60 |
$6.92 |
Cefepime-AFT (AFT) |
1% |
1 August 2015 |
1 October 2015 |
DBL Cefepime (Hospira) |
|
Cefoxitin sodium |
Inj 1 g vial; 10 vial |
$74.25 for 5 vials |
$58.00 for 10 vials |
Cefoxitin Actavis (Actavis) |
1% |
1 November 2015 |
1 January 2016 |
Hospira (Hospira) |
|
Citalopram hydrobromide |
Tab 20 mg; 84 tablet, blister pack |
$2.34 |
$1.79 |
PSM Citalopram (API) |
1% |
1 October 2015 |
1 December 2015 |
Arrow-Citalopram (Actavis) |
|
Cyclizine hydrochloride |
Tab 50 mg; 20 tablet, blister pack |
$0.59 per 10 tablets |
$0.59 per 20 tablets |
Nauzene (Actavis) |
1% |
1 November 2015 |
1 January 2016 |
Nausicalm (AFT) |
|
Desferrioxamine mesilate |
Inj 500 mg vial; 10 vials |
$109.89 |
$51.52 |
Desferal (Novartis) |
1% |
1 December 2015 |
1 February 2016 |
Hospira (Hospira) |
|
Dexamethasone4 |
Tab 0.5 mg; 30 tablet, bottle pack |
$5.87 per 100 tablets of tab 1 mg |
$0.88 per 30 tablets of 0.5 mg |
Dexmethsone (Aspen) |
1% |
1 November 2015 |
1 January 2016 |
Douglas (Douglas) |
|
Dexamethasone |
Tab 4 mg; 30 tablet, bottle pack |
$8.16 per 100 tablets |
$1.84 per 30 tablets |
Dexmethsone (Aspen) |
1% |
1 November 2015 |
1 January 2016 |
Douglas (Douglas) |
|
Dopamine hydrochloride |
Inj 40 mg per ml, 5 ml ampoule; 5 ampoules |
$69.77 per 10 ampoules |
$16.89 per 5 ampoules |
DBL Sterile Dopamine Concentrate (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
Martindale (Max Health) |
|
Doxorubicin hydrochloride3 |
Inj 2 mg per ml, 25 ml; 1 vial |
$17.00 |
$11.50 |
Doxorubicin Ebewe (Sandoz) |
1% |
1 December 2015 |
1 February 2016 |
Arrow-Doxorubicin (Actavis) |
|
Doxorubicin hydrochloride3 |
Inj 2 mg per ml, 100 ml vial; 1 vial |
$65.00 |
$46.00 |
Doxorubicin Ebewe (Sandoz) |
1% |
1 December 2015 |
1 February 2016 |
Arrow-Doxorubicin (Actavis) |
|
Lansoprazole |
Cap 15 mg; 100 capsule, bottle pack |
$2.00 per 28 |
$5.08 per 100 |
Lanzol Relief (Mylan) |
1% |
1 November 2015 |
1 January 2016 |
Solox (Douglas) |
|
Lansoprazole |
Cap 30 mg; 100 capsule, bottle pack |
$2.32 per 28 |
$5.93 per 100 |
Lanzol Relief (Mylan) |
1% |
1 November 2015 |
1 January 2016 |
Solox (Douglas) |
|
Metformin hydrochloride |
Tab immediate-release 850 mg; 500 tablet, bottle pack |
$10.10 |
$7.82 |
Metformin Mylan (Mylan) |
1% |
1 October 2015 |
1 December 2015 |
Apotex (Apotex) |
|
Paracetamol |
Suppos 125 mg; 10 suppositories |
$7.49 per 20 |
$3.69 per 10 |
Gacet (AFT) |
1% |
1 October 2015 |
1 December 2015 |
Panadol (GSK) |
|
Paracetamol |
Suppos 250 mg; 10 suppositories |
$14.40 per 20 |
$3.79 per 10 |
Gacet (AFT) |
1% |
1 October 2015 |
1 December 2015 |
Panadol (GSK) |
|
Pioglitazone |
Tab 15 mg; 90 tablet, bottle pack |
$1.50 per 28 tablets |
$3.47 per 90 tablets |
Vexazone (Mylan) |
1% |
1 October 2015 |
1 December 2015 |
Pizaccord (Douglas) |
|
Pioglitazone |
Tab 30 mg; 90 tablet, bottle pack |
$2.50 per 28 tablets |
$5.06 per 90 tablets |
Vexazone (Mylan) |
1% |
1 October 2015 |
1 December 2015 |
Pizaccord (Douglas) |
|
Pioglitazone |
Tab 45 mg; 90 tablet, bottle pack |
$3.50 per 28 tablets |
$7.10 per 90 tablets |
Vexazone (Mylan) |
1% |
1 October 2015 |
1 December 2015 |
Pizaccord (Douglas) |
-
Acetylcysteine inj 200 mg per ml, 30 ml to be delisted from Section H from 1 September 2015.
-
Hospira’s brand of carboplatin (PCT only – Specialist) will be listed in Section B of the Pharmaceutical Schedule from 1 July 2015. The subsidy for carboplatin inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $0.13 per 1 mg to $0.08 per 1 mg from 1 September 2015. Carboplatin Ebewe inj 10 mg per ml, 100 ml vial to be delisted from Section H from 1 September 2015.
-
The price and subsidy of doxorubicin hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 December 2015. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $0.37 per 1 mg to $0.25 per 1 mg from 1 February 2016. Doxorubicin hydrochloride inj 50 mg vial to be delisted from Section H from 1 February 2016.
-
Dexamethasone tab 1 mg to be delisted 1 January 2016.
-
Tenders awarded to pharmaceuticals where no brand is listed.
Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack Price | Hospital Supply Brand (Supplier) | DV Limit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Dobutamine hydrochloride |
Inj 12.5 mg per ml, 20 ml ampoule; 5 ampoules |
$24.45 |
Dobutamine-Claris (AFT) |
1% |
1 November 2015 |
1 January 2016 |
|
Daptomycin |
Inj 350 mg vial; 1 vial |
$175.16 |
Cubicin (Novartis) |
1% |
1 July 2015 |
1 September 2015 |
|
Daptomycin |
Inj 500 mg vial; 1 vial |
$243.52 |
Cubicin (Novartis) |
1% |
1 July 2015 |
1 September 2015 |
|
Doxorubicin hydrochloride 1 |
Inj 2 mg per ml, 50 ml vial; 1 vial |
$23.00 |
Doxorubicin Ebewe (Sandoz) |
1% |
1 December 2015 |
1 February 2016 |
|
Linezolid |
Inj 2 mg per ml, 300 ml bag; 10 bags |
$1,650.00 |
Zyvox (Pfizer) |
1% |
1 July 2015 |
1 September 2015 |
|
Linezolid |
Oral liq 20 mg per ml; 150 ml |
$775.00 |
Zyvox (Pfizer) |
1% |
1 July 2015 |
1 September 2015 |
|
Linezolid |
Tab 600 mg; 10 tablet, blister pack |
$800.00 |
Zyvox (Pfizer) |
1% |
1 July 2015 |
1 September 2015 |
|
Pancreatic enzyme |
Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease; 100 capsule, bottle pack |
$94.38 |
Creon 25000 (Abbott) |
1% |
1 August 2015 |
1 October 2015 |
|
Pancreatic enzyme |
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease; 100 capsule, bottle pack |
$34.93 |
Creon 10000 (Abbott) |
1% |
1 August 2015 |
1 October 2015 |
-
The price and subsidy of doxorubicin hydrochloride (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 December 2015. The subsidy for doxorubicin hydrochloride inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $0.37 per 1 mg to $0.25 per 1 mg from 1 February 2016.
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 7 November 2013, and the 2014/15 Invitation to Tender, dated 6 November 2014:
2013/14 Invitation to Tender
| Chemical name | Line item |
|---|---|
|
Brinzolamide |
Eye Drops 1% |
|
Cetirizine hydrochloride |
Tab 10 mg |
|
Hydrocortisone |
Crm 1% (pack size greater than 100 g) |
|
Hydrocortisone |
Crm 1% (pack size greater than 15 g and less than 100 g) |
|
Sodium chloride |
Inj 0.9%, 5 ml |
|
Sodium chloride |
Inj 0.9%, 10 ml |
|
Sodium chloride |
Inj 0.9%, 20 ml |
|
Sodium chloride |
Soln 0.9% for irrigation, 30 ml |
|
Travoprost |
Eye drops 0.004% |
|
Water for Injection |
Purified for inj 5 ml |
|
Water for Injection |
Purified for inj 10 ml |
|
Water for Injection |
Purified for inj 20 ml |
|
Wool fat |
Crm |
|
Zinc and castor oil |
Oint BP (pack size greater than 30 g) |
2014/15 Invitation to Tender
| Chemical name | Line item |
|---|---|
|
Ambrisentan |
Tab 5 mg |
|
Ambrisentan |
Tab 10 mg |
|
Carboplatin |
Inj 10 mg per ml, 100 ml |
|
Doxorubicin hydrochloride |
Inj 10 mg |
|
Enoxaparin sodium |
Inj 20 mg per 0.2 ml |
|
Enoxaparin sodium |
Inj 40 mg per 0.4 ml |
|
Enoxaparin sodium |
Inj 60 mg per 0.6 ml |
|
Enoxaparin sodium |
Inj 80 mg per 0.8 ml |
|
Enoxaparin sodium |
Inj 100 mg per ml, 1 ml |
|
Enoxaparin sodium |
Inj 120 mg per 0.8 ml |
|
Enoxaparin sodium |
Inj 150 mg per ml, 1 ml |
|
Fluorouracil sodium |
Inj 50 mg per ml, 10 ml |
|
Idarubicin Hydrochloride |
Cap 5 mg |
|
Idarubicin Hydrochloride |
Cap 10 mg |
|
Lidocaine [Lignocaine] Hydrochloride |
Inj 1%, 2 ml |
|
Lidocaine [Lignocaine] Hydrochloride |
Inj 2%, 2 ml |
|
Mitozantrone |
Inj 2 mg per ml, 5 ml |
|
Mitozantrone |
Inj 2 mg per ml, 12.5 ml |
|
Pancreatic enzyme |
Cap EC 24,000-25,000 BP u lipase, 22,000-23,000 BP u amylase and 1,000-1,500 BP u protease |
|
Promethazine Hydrochloride |
Inj 25 mg per ml, 2 ml |
|
Propranolol |
Tab 10 mg |
|
Propranolol |
Tab 40 mg |
|
Single chamber empty IV infusion bags |
DEHP-free IV infusion bag, 250 ml |
|
Single chamber empty IV infusion bags |
DEHP-free IV infusion bag, 500 ml |
|
Single chamber empty IV infusion bags |
DEHP-free IV infusion bag, 1,000 ml |
|
Single chamber empty IV infusion bags |
Latex-free IV infusion bag, 250 ml |
|
Single chamber empty IV infusion bags |
Latex-free IV infusion bag, 500 ml |
|
Single chamber empty IV infusion bags |
Latex-free IV infusion bag, 1,000 ml |
|
Single chamber empty IV infusion bags |
PVC-free IV infusion bag, 250ml |
|
Single chamber empty IV infusion bags |
PVC-free IV infusion bag, 500 ml |
|
Single chamber empty IV infusion bags |
PVC-free IV infusion bag, 1,000 ml |
|
Single chamber empty IV infusion bags |
PVC-free, DEHP-free and latex-free IV infusion bag, 250 ml |
|
Single chamber empty IV infusion bags |
PVC-free, DEHP-free and latex-free IV infusion bag, 500 ml |
|
Single chamber empty IV infusion bags |
PVC-free, DEHP-free and latex-free IV infusion bag, 1,000 ml |
|
Testosterone |
Transdermal patch 2.5 mg |
|
Testosterone |
Transdermal patch 5 mg |
|
Tobramycin |
Inj 100 mg per ml, 5 ml vial |
|
Tobramycin |
Powder BP |
|
Trimethoprim with sulphamethoxazole [Co-trimoxazole] |
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule |
For products included in the 2013/14 and 2014/15 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.